Abstract
Class 2 and 3 non-V600E BRAF mutations are oncogenic drivers in many cancer types. Currently, there are no established targeted therapies with proven efficacy for cancers with non-V600E BRAF mutations. We developed the investigator-initiated, Phase II BEAVER clinical trial (NCT03839342) to evaluate the efficacy of BRAF and MEK inhibitors in patients with non-V600E BRAF mutations. The best objective response rate was 14% (3/21). By analyzing genomic data from patient tumors, circulating tumor DNA (ctDNA), patient-derived xenograft (PDX) models generated from enrolled patients, and functional genomics of Class 2 & 3 BRAF mutant cell lines, we discovered MAPK-dependent and independent mechanisms of intrinsic and acquired resistance to BRAF/MEK inhibition. These included the acquisition of new mutations in NRAS, MAP2K1, RAF1, and RB in ctDNA at the time of disease progression. We observed an enrichment for alterations in genes that regulate cell cycle progression amongst non-responders and increased expression of genes mediating cell cycle progression in tumors Class 2 BRAF mutant cell lines with acquired resistance to BRAF/MEK inhibitors. In Class 3 BRAF mutant cancers specifically, PTPN11 (SHP2) was an essential gene. CDK4/6 and SHP2 were found to mediate intrinsic resistance to BRAF/MEK inhibition in Class 2 & 3 BRAF mutant tumors. Therapeutic strategies combining CDK4/6 or SHP2 inhibitors with BRAF/MEK inhibitors were more effective than BRAF/MEK inhibitors alone in vitro and in vivo, highlighting the need to explore therapeutic targets outside of the MAPK pathway in these hard-to-treat Class 2 & 3 BRAF mutant cancers.
Competing Interest Statement
Dr. Rose has provided consultation for Advanced Accelerator Applications/Novartis, EMD Serrono and Pfizer. Dr. Rose reports research funding from AstraZeneca (Inst), Novartis (Inst), Merck (Inst), Seattle Genetics (Inst), Pfizer (Inst), and Essa Pharma (Inst). Dr. Soria Bretones is an employee of Repare Therapeutics Dr. King reports research funding from Pfizer (Inst) and is an employee of GeneDx, Gaithersburg MD. Dr. Pugh has provided consultation for AstraZeneca, Chrysalis Biomedical Advisors, and Merck (compensated); and receives research support (institutional) from Roche/Genentech and AstraZeneca. Dr. Shepherd has provided consultation for AstraZeneca. Dr. Razak reported a consulting/advisory role with Adaptimmune, Bayer, GlaxoSmithKline, Medison, Inhibrx, research funding from Deciphera, Karyopharm Therapeutics, Pfizer, Roche/Genentech, Bristol Myers Squibb, MedImmune, Amgen, GlaxoSmithKline, Blueprint Medicines, Merck, AbbVie, Adaptimmune, Iterion Therapeutics, Neoleukin Therapeutics, Daiichi Sankyo, Symphogen, Rain Therapeutics, and expert testimony with Medison. Dr. Hansen reported receiving research funds (paid to institution) from: Advancell, AVEO, BMS, Janssen, Macrogenics, MSD, Seagen, Roche and Tyra Biosciences. Consulting fees (paid personally) from: Astellas, Bayer, Eisai, MSD. Dr. Bedard reported an uncompensated consulting/advisory role with BMS, Pfizer, Seattle Genetics, Lilly, Amgen, Merck, Gilead Sciences, Repare and research funding from Bristol Myers Squibb (Inst), Sanofi (Inst), AstraZeneca (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), Novartis (Inst), Nektar (Inst), Merck (Inst), Seattle Genetics (Inst), Immunomedics (Inst), Lilly (Inst), Amgen (Inst), Bicara Therapeutics (Inst), Zymeworks (Inst), Bayer (Inst), Medicenna (Inst), Day One Biopharmaceuticals (Inst). Dr. Siu reported consultant/advisory roles for: Merck, Pfizer, AstraZeneca, Roche, GlaxoSmithKline, Voronoi, Arvinas, Navire, Relay, Marengo, Daiichi Sankyo, Amgen, Medicenna, LTZ Therapeutics, Tubulis, Marengo, Nerviano, Pangea, Incyte, Gilead; Institutions receives grant/research support for clinical trials from: Merck, Novartis, Bristol-Myers Squibb, Pfizer/Seattle Genetics, Boerhinger-Ingelheim, GlaxoSmithKline, Roche/Genentech, AstraZeneca/Medimmune, Bayer, Abbvie, Amgen, Symphogen, EMD Serono, 23Me, Daiichi Sankyo, Gilead, Marengo, Incyte, LegoChem, Loxo/Eli Lilly, Medicenna, Takara; Spouse has leadership position: Treadwell Therapeutics; Spouse has stock ownership: Agios. Dr. Spreafico reported a consulting/advisory role with Merck, Bristol-Myers Squibb, and Alents andgrant/research funding from Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma/Pfizer, GSK, NuBiyota, Oncorus, Treadwell, Amgen, ALX Oncology, Nubiyota, Genentech, Seagen, Servier, Incyte, Alentis. All other co-authors report no conflicts of interest.
Clinical Trial
NCT03839342
Funding Statement
The BEAVER clinical trial was sponsored by the Cancer Genomics Program of the Princess Margaret Cancer Centre. Funding for clinical operations of the BEAVER trial were provided by Pfizer. Exploratory objectives and preclinical experiments were funded by a Conquer Cancer Foundation Young Investigator Award and a Career Development Award to AANR, a Canadian Cancer Society Challenge Grant (#707457) to AANR and AS, a Canadian Institutes of Health Research (CIHR) Project Grant (#180379) to AANR and start-up funding from the TransMedTech Institute and Apogee Canada Research Excellence Fund and the Jewish General Hospital Foundation to AANR. Additional infrastructure support to carry out this research was provided by a John R. Evans Leaders Fund award (#42153) from the Canada Foundation for Innovation to AANR with matched funds from the Province of Quebec. AANR acknowledges salary support from a Fonds de Recherche du Quebec Sante (FRQS) Clinical Research Scholar Award; J.M. is the recipient of an Elizabeth Steffen Memorial Fellowship from McGill University Faculty of Medicine and Health Sciences and a FRQS doctoral award, ER is a recipient of a Marathon of Hope Data Science Award and a FRQS doctoral award, M.R. and I.S.B. are recipients of CIHR postdoctoral fellowships; IEE is a Peter Quinlan Fellow in Oncology from McGill University Faculty of Medicine and Health Sciences and a recipient of a FRQS postdoctoral fellowship. CM is a recipient of a CIHR Canada Graduate Scholarships-Masters (CGS-M) award and a Masters Research Training Award from the Canadian Cancer Society.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the Research Ethics Board of the University Health Network gave ethical approval for this work (REB ID: 18-6324).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
